Clinical trial NCT03898401: Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis
Official title: Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Senile Vaginitis
Lead sponsor: Ain Shams University
Sponsor class: OTHER
Collaborators: name: Netherlands: Ministry of Health, Welfare and Sports
First posted: 2019-04-02
Enrollment: 30
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: 30 postmenopausal females with senile vaginitis will be enrolled with score of \<15 on the Gloria Bachman Vaginal Health Index (VHI) intramucosal injections of PRP will be adminstered and perform clinical evaluations at 0, 1, 3, and 6 months.

Detailed description: 30 postmenopausal females with senile vaginitis will be enrolled with score of \<15 on the Gloria Bachman Vaginal Health Index (VHI) intramucosal injections of PRP will be adminstered and perform clinical evaluations at 0, 1, 3, and 6 months.

The patients will be seen in Ain shams university gynecological clinic and will not be paid either to receive the procedure or to complete the survey. All patients were fully informed of the innovative therapeutic and experimental nature of the localized PRP injection and consented to the procedure.

The materials and equipment included the following:

1. 5 cc syringes.
2. 27 gauge needles.
3. Centrifuge with proprietary collection system.
4. Calcium chloride 10% (for activation of PRP).
5. and a topical anesthetic cream compounded with a base that prevents irritation and promotes absorption through the vaginal mucosa. Active ingredients will be as follows: bupivicaine, lidocaine, and tetracaine with percent concentrations of 20/8/8 respectively.

First, a topical anesthetic cream will be applied to the posterior vaginal wall. Delaying the PRP injection for 20 minutes after anesthetic application achieved complete or near complete analgesia for the procedure. Peripheral blood will be drawn from the arm and centrifuged to yield 5 cc of PRP. The Regen® system concentrates 5ml of PRP from 10 ml of whole blood using a gel separator.

Study Interventions:

After isolation of the PRP, calcium chloride (0.5ml) was added to the 5 ml of PRP isolate to activate the thrombin cascade, thereby causing degranulation of platelets, releasing growth factors and cytokines, and starting the transformation of the PRP to platelet rich fibrin matrix (PRFM) Before the PRFM became too gelatinous for passing through a needle (less than 10 minutes), two injections will be given through a 27-gauge needle in the posterior vaginal wall and perform clinical evaluations at 0, 1, 3, and 6 months.

Eligibility criteria: Inclusion Criteria:

* Postmenopausal for at least 3 years.
* Vaginal health index \<15.
* Any parity.

Exclusion Criteria:

* Women with vaginal infection.
* Women taking estrogen therapy for senile vaginitis.
* Any patient with medical disorder especially diabetes mellitus.
* Previous vaginal surgery as fistula repair or classical repair.
* Vaginal prolapse
* Any patient taking chemo or radiotherapy.

Primary outcomes:
measure: Evaluation of vaginal mucosa using vaginal health index score
timeFrame: 6 months
Secondary outcomes:
measure: Female Sexual Distress (FSD) scale
timeFrame: 6 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain shams University
state: Elabbasia
city: Cairo
country: Egypt
facility: Ain shams university hospital
Study officials:
affiliation: Ain Shams University
name: Rasha Medhat, Professor
role: PRINCIPAL_INVESTIGATOR
References: